Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis

Brenner, I. R., Flanagan, C. F., Penazzato, M., Webb, K. A., Horsfall, S. B., Hyle, E. P., Abrams, E., Bacha, J., Neilan, A. M., Collins, I. J., Desmonde, S., Crichton, S., Davies, M.-A., Freedberg, K. A., & Ciaranello, A. L. (2024). Cost-effectiveness of viral load testing for transitioning antiretroviral therapy-experienced children to dolutegravir in South Africa: a modelling analysis. The Lancet Global Health, 12(12), e2068–e2079. https://doi.org/10.1016/s2214-109x(24)00381-4
Authors:
Isaac Ravi Brenner
Clare F Flanagan
Martina Penazzato
Karen A Webb
Stephanie B Horsfall
Emily P Hyle
Elaine Abrams
Jason Bacha
Anne M Neilan
Intira Jeannie Collins
Sophie Desmonde
Siobhan Crichton
Mary-Ann Davies
Kenneth A Freedberg
Andrea L Ciaranello
Affiliated Authors:
Elaine Abrams
Columbia Affiliation:
Subjects:
Pyridones (MeSH)
Oxazines (MeSH)
Cost-Benefit Analysis (MeSH)
HIV Infections (MeSH)
Heterocyclic Compounds, 3-Ring (MeSH)
Piperazines (MeSH)
Viral Load (MeSH)
Dideoxynucleosides (MeSH)
Lamivudine (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1016/s2214-109x(24)00381-4
PMID:
39577977
DOI:
10.1016/s2214-109x(24)00381-4
Journal:
Lancet Global Health
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: